IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan

Management provides Nasdaq Hearing Panel with a comprehensive executable plan for long term compliance

LAWRENCEVILLE, N.J., July 15, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Nasdaq Hearing Panel has granted its request for an exception to complete its compliance plan, allowing the Company to maintain its listing on the Nasdaq Stock Market.

Read more at globenewswire.com